Prostate cancer hormone treatments need new warnings about an increased risk of diabetes and heart problems including sudden death. The medications include Abbott Laboratories Inc's Lupron, AstraZeneca's Zoladex and Sanofi-Aventis SA's Eligard.
According to the FDA, the drugs, known as gonadotropin-releasing hormone (GnRH) agonists, are used to suppress the production of testosterone, a hormone that helps fuel prostate cancer growth. These particular drugs are approved to relieve symptoms of advanced prostate cancer in a treatment known as androgen deprivation therapy.
Other GnRH drugs include Watson Pharmaceuticals Inc's Trelstar and Endo Pharmaceuticals Holdings Inc's Vantas.
Posted by Louisville, Kentucky lawyer Larry Jones. Larry can be reached at larry@jonesward.com or by using his toll-free number 1-888-KYLAW22.
